



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

# Cosentyx Intravenous (secukinumab)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City	State	Zip
City	State	Zip	Patient Phone:		

**Urgency:**  
 Standard  Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

**Medication requested:**  
 Cosentyx 125mg/5ml IV

Dose and Quantity: \_\_\_\_\_ Duration of therapy: \_\_\_\_\_ J-Code: \_\_\_\_\_  
 Frequency of administration: \_\_\_\_\_ ICD10: \_\_\_\_\_

What is your patient's current weight? \_\_\_\_\_

Is this a new start or continuation of therapy with the requested medication? If patient has been taking samples, please pick "new start."  
 new start of therapy  continuation of therapy

**If continuation of therapy:**  
 (if continuation of therapy) Has the patient demonstrated a beneficial response to this medication?  Yes  No  
 (if no) Please provide support for continued use in your patient.

*(Please note: there are different preferred products depending on your patient's plan. Please refer to the applicable Cigna health care professional resource [e.g. cignaforhcp.com] to determine benefit availability and the terms and conditions of coverage)*

**Where will this medication be obtained?**

<input type="checkbox"/> Accredo Specialty Pharmacy**	<input type="checkbox"/> Home Health / Home Infusion vendor
<input type="checkbox"/> Hospital Outpatient	<input type="checkbox"/> Physician's office stock (billing on a medical claim form)
<input type="checkbox"/> Retail pharmacy	<b>**Cigna's nationally preferred specialty pharmacy</b>
<input type="checkbox"/> Other (please specify): _____	

**\*\*Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557**

**Facility and/or doctor dispensing and administering medication:**

Facility Name: \_\_\_\_\_ State: \_\_\_\_\_ Tax ID#: \_\_\_\_\_  
 Address (City, State, Zip Code): \_\_\_\_\_

**Where will this drug be administered?**

<input type="checkbox"/> Patient's Home	<input type="checkbox"/> Physician's Office
<input type="checkbox"/> Hospital Outpatient	<input type="checkbox"/> Other (please specify): _____

**NOTE:** Per some Cigna plans, infusion of medication **MUST** occur in the least intensive, medically appropriate setting.

Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager?  Yes  No (provide medical necessity rationale): \_\_\_\_\_

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?  Yes  No

**Diagnosis related to use:**

- Ankylosing spondylitis (AS)
- Crohn's disease (CD)
- Enthesitis-related arthritis
- Non-radiographic axial spondyloarthritis (nr-axSpA)
- Plaque psoriasis (PsO)
- Psoriatic arthritis (PsA)
- Rheumatoid Arthritis (RA)
- other (please specify):

**Clinical Information:**

Besides the drug being requested, other biologics and tsDMARDs (targeted synthetic disease-modifying antirheumatic drugs) include Actemra, adalimumab (Humira and all biosimilars), Adbry, Bimzelx, Cibinqo, Cimzia, Enbrel, Entyvio, Ilumya, infliximab (Remicade and all biosimilars), Kevzara, Kineret, Litfulo, Olumiant, Omvoh, Orenzia, Otezla, Rinvoq, rituximab (Rituxan and all biosimilars), Siliq, Simponi Aria, Simponi, Skyrizi, Sotyktu, Stelara, Taltz, Tremfya, Tysabri, Velsipity, Xeljanz, Zeposia. Which of the following best describes your patient's situation?

- The patient is NOT taking any other biologic or tsDMARD at this time, nor will they in the future. The requested drug is the only biologic or tsDMARD the patient is/will be using.
- The patient is currently on another biologic or tsDMARD, but this drug will be stopped and the requested drug will be started
- The patient is currently on another biologic or tsDMARD, and the requested drug will be added. The patient will continue to take both drugs together.
- The patient is currently on BOTH the requested drug AND another biologic or tsDMARD
- Other

(if other/more than the requested drug) Please provide the rationale for concurrent use.

(if AS, PsA) Has your patient already tried a biologic or tsDMARD (targeted synthetic disease-modifying antirheumatic drug)?  Yes  No

(if PsA) Does your patient primarily have axial disease -OR- non-axial disease?

- Non-axial disease
- Axial disease

(if non-axial disease) The covered alternatives are DMARDs (disease-modifying anti-rheumatic drugs). If your patient has tried any DMARDs, please provide drug strength, date(s) taken and for how long, and what the documented results were of taking this drug, including any intolerances or adverse reactions your patient experienced. If DMARDs were not tried, please provide details why your patient can't try this alternative

(if non-axial disease) Per the information provided above, which of the following is true for your patient in regard to the covered alternatives?

- The patient tried a DMARD, but it didn't work.
- The patient tried DMARDs, but did not tolerate them.
- The patient cannot try DMARDs because of a contraindication to each.
- Other

(if axial disease) The covered alternatives are DMARDs (disease-modifying anti-rheumatic drugs) and nonsteroidal anti-inflammatory drugs (NSAIDs). If your patient has tried any DMARDs or NSAIDs, please provide drug name and strength, date(s) taken and for how long, and what the documented results were of taking each drug, including any intolerances or adverse reactions your patient experienced. If DMARDs or NSAIDs were NOT tried, please provide details why your patient can't try these drugs.

(if axial disease) Per the information provided above, which of the following is true for your patient in regard to the covered alternatives?

- The patient tried a DMARD or NSAID, but it didn't work.
- The patient tried DMARDs and NSAIDs, but did not tolerate them.
- The patient cannot try DMARDs or NSAIDs because of a contraindication to each.
- Other

(if PsA) Is this medication being prescribed by, or in consultation with, a rheumatologist or dermatologist?  Yes  No

(if AS) The covered alternatives are nonsteroidal anti-inflammatory drugs (NSAIDs). If your patient has tried any NSAIDs, please provide the drug name and strength, date(s) taken and for how long, and what the documented results were of taking each drug, including any intolerances or adverse reactions your patient experienced. If NSAIDs were NOT tried, please provide details why your patient can't try these drugs.

(if AS) Per the information above, which of the following is true for your patient in regard to the covered alternatives?

- The patient tried an NSAID, but it didn't work.
- The patient tried an NSAID, but they did not tolerate it.
- The patient cannot try an NSAID because of a contraindication to this drug.
- Other

(if AS, nr-axSpA) Is this medication being prescribed by, or in consultation with, a rheumatologist?

Yes  No

(if nr-axSpA) Does your patient have EITHER of the following objective signs of inflammation?

- C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory.
- Sacroiliitis reported on magnetic resonance imaging (MRI)
- Both of the above
- None of the above

**Additional Information:** Please provide clinical rationale for the use of this drug for your patient (pertinent patient history, alternatives tried, any inability to use alternatives above or standard therapy, etc). Please include drug name(s), date(s) taken and for how long, and what the documented results were of taking each drug, including any intolerances or adverse reactions your patient experienced.

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at: [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v070124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005